BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, Bentz JS, Shroyer KR. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol. 2008;16:24-31. [PMID: 18091324 DOI: 10.1097/pai.0b013e31802e91d0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Silvers MA, Deja S, Singh N, Egnatchik RA, Sudderth J, Luo X, Beg MS, Burgess SC, DeBerardinis RJ, Boothman DA, Merritt ME. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. J Biol Chem 2017;292:18203-16. [PMID: 28916726 DOI: 10.1074/jbc.M117.813923] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 8.2] [Reference Citation Analysis]
2 Osman NATAG, Abd El-Maqsoud NMR, El Gelany SAA. Correlation of NQO1 and Nrf2 in Female Genital Tract Cancer and Their Precancerous Lesions (Cervix, Endometrium and Ovary). World J Oncol 2015;6:364-74. [PMID: 28983331 DOI: 10.14740/wjon931w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
3 Pereyra CE, Dantas RF, Ferreira SB, Gomes LP, Silva-Jr FP. The diverse mechanisms and anticancer potential of naphthoquinones. Cancer Cell Int 2019;19:207. [PMID: 31388334 DOI: 10.1186/s12935-019-0925-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 13.3] [Reference Citation Analysis]
4 Lewis JE, Singh N, Holmila RJ, Sumer BD, Williams NS, Furdui CM, Kemp ML, Boothman DA. Targeting NAD+ Metabolism to Enhance Radiation Therapy Responses. Semin Radiat Oncol 2019;29:6-15. [PMID: 30573185 DOI: 10.1016/j.semradonc.2018.10.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
5 Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, Chen L. Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res. 2014;33:14. [PMID: 24499631 DOI: 10.1186/1756-9966-33-14] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
6 Zheng Y, Zhang H, Guo Y, Chen Y, Chen H, Liu Y. X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells. BMC Cancer 2021;21:1234. [PMID: 34789190 DOI: 10.1186/s12885-021-08979-y] [Reference Citation Analysis]
7 Hosein AN, Beg MS. Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications. Curr Oncol Rep 2018;20:56. [PMID: 29752600 DOI: 10.1007/s11912-018-0699-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
8 Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone. Cell Death Dis 2015;6:e1599. [PMID: 25590809 DOI: 10.1038/cddis.2014.564] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]
9 Yu H, Liu H, Wang LE, Wei Q. A functional NQO1 609C& gt; T polymorphism and risk of gastrointestinal cancers: a meta-analysis. PLoS One. 2012;7:e30566. [PMID: 22272361 DOI: 10.1371/journal.pone.0030566] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
10 Jiang ZN, Ahmed SMU, Wang QC, Shi HF, Tang XW. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival. World J Gastroenterol 2021; 27(22): 3085-3096 [PMID: 34168410 DOI: 10.3748/wjg.v27.i22.3085] [Reference Citation Analysis]
11 Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012;83:1033-40. [PMID: 22209713 DOI: 10.1016/j.bcp.2011.12.017] [Cited by in Crossref: 181] [Cited by in F6Publishing: 170] [Article Influence: 16.5] [Reference Citation Analysis]
12 Chakrabarti G, Gerber DE, Boothman DA. Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. Clin Pharmacol 2015;7:57-68. [PMID: 25870517 DOI: 10.2147/CPAA.S79760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
13 Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 2011;10:37. [PMID: 21489257 DOI: 10.1186/1476-4598-10-37] [Cited by in Crossref: 135] [Cited by in F6Publishing: 142] [Article Influence: 12.3] [Reference Citation Analysis]
14 Lee WS, Ham W, Kim J. Roles of NAD(P)H:quinone Oxidoreductase 1 in Diverse Diseases. Life (Basel) 2021;11:1301. [PMID: 34947831 DOI: 10.3390/life11121301] [Reference Citation Analysis]
15 Ferraz da Costa DC, Pereira Rangel L, Martins-Dinis MMDDC, Ferretti GDDS, Ferreira VF, Silva JL. Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues. Molecules 2020;25:E893. [PMID: 32085381 DOI: 10.3390/molecules25040893] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
16 Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. J Surg Oncol 2017;116:83-8. [PMID: 28346693 DOI: 10.1002/jso.24624] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
17 Chakrabarti G, Silvers MA, Ilcheva M, Liu Y, Moore ZR, Luo X, Gao J, Anderson G, Liu L, Sarode V, Gerber DE, Burma S, DeBerardinis RJ, Gerson SL, Boothman DA. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. Sci Rep 2015;5:17066. [PMID: 26602448 DOI: 10.1038/srep17066] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
18 Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17:275-85. [PMID: 21224367 DOI: 10.1158/1078-0432.CCR-10-1983] [Cited by in Crossref: 83] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
19 Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Y, Burma S, Scaglioni PP, Cantley LC, DeBerardinis RJ, Kimmelman AC, Lyssiotis CA, Boothman DA. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab 2015;3:12. [PMID: 26462257 DOI: 10.1186/s40170-015-0137-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 10.7] [Reference Citation Analysis]
20 Cui X, Li L, Yan G, Meng K, Lin Z, Nan Y, Jin G, Li C. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC Cancer 2015;15:244. [PMID: 25885439 DOI: 10.1186/s12885-015-1271-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
21 Li Z, Zhang Y, Jin T, Men J, Lin Z, Qi P, Piao Y, Yan G. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer. 2015;15:207. [PMID: 25880877 DOI: 10.1186/s12885-015-1227-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
22 Ma Y, Kong J, Yan G, Ren X, Jin D, Jin T, Lin L, Lin Z. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer. 2014;14:414. [PMID: 24912939 DOI: 10.1186/1471-2407-14-414] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
23 Li C, Cheng L, Wu H, He P, Zhang Y, Yang Y, Chen J, Chen M. Activation of the KEAP1‑NRF2‑ARE signaling pathway reduces oxidative stress in Hep2 cells. Mol Med Rep 2018;18:2541-50. [PMID: 30015918 DOI: 10.3892/mmr.2018.9288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
24 Akhtari FS, Green AJ, Small GW, Havener TM, House JS, Roell KR, Reif DM, McLeod HL, Wiltshire T, Motsinger-Reif AA. High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. PLoS Genet 2021;17:e1009732. [PMID: 34437536 DOI: 10.1371/journal.pgen.1009732] [Reference Citation Analysis]
25 Wang M, Topalovski M, Toombs JE, Wright CM, Moore ZR, Boothman DA, Yanagisawa H, Wang H, Witkiewicz A, Castrillon DH, Brekken RA. Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. Cancer Res 2015;75:5058-69. [PMID: 26577699 DOI: 10.1158/0008-5472.CAN-15-0744] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]